



VISEN LAUNCHES NEW *Cat K FAST™* FLUORESCENCE MOLECULAR IMAGING AGENT

Expands VisEn's Leading Fluorescence Molecular Imaging Agent Portfolio to Enable Breakthrough Readouts of Cathepsin K Biomarkers in Research and Drug Development

BEDFORD, MA (July 7, 2009)-- VisEn Medical Inc., a leader in fluorescence *in vivo* imaging from research through medicine, announced today the commercial launch of its new *Cat K FAST™* imaging agent for measuring and monitoring cathepsin K activity associated with disease progression and therapeutic response *in vivo*. Cathepsin K expression is well known as a key biomarker and therapeutic target in a range of bone-related diseases, including cancer metastasis to bone, as well as in atherosclerosis. The new *Cat K FAST™* agent is expected to significantly expand research and enhance drug development in these areas by enabling real time imaging of cathepsin K activity.

Cat K FAST™ represents an additional protease-sensing agent developed and commercially launched based on VisEn's new *FAST* ("Fluorescent Activatable Sensor Technology") *in vivo* agent platform. *FAST* agents are based on high-performance, activatable smaller molecules that combine biomarker specificity with optimized biocompatibility and pharmacokinetics for precise measurement and monitoring of key disease biomarkers *in vivo*.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts *in vivo*. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense®, IntegriSense™, AngioSense™, OsteoSense® and MMPsense™. VisEn also offers its specialized *in vivo* agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes for custom agent development, and its NanoSpark® labeling nanoparticles, all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in *in vivo* imaging. All VisEn agents and labels, including the new *Cat K FAST™* agent, are designed for *in vivo* biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT™) imaging systems, or for general use along with other non-quantitative fluorescence *in vivo* imaging systems. VisEn agents are also designed to enable *in vitro* biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's *in vivo* fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT™) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy *in vivo*. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.



Media Contact:

Robert Sandler

VP, Marketing
VisEn Medical Inc.
45 Wiggins Avenue
O. 647.350.1881
C. 416.274.8166
E. rsandler@visenmedical.com
W. www.visenmedical.com

Peter Steinerman

Principal
Steinerman Biomedical Comm.
O. 516-374-3031
C. 516 641 8959
E. PRSteinerman@aol.com